PARSIPPANY, N.J., Nov. 6, 2026 /PRNewswire/ -- Onkos Surgical, Inc. today announced a new FDA 510(k) clearance for its NanoCept® Antibacterial Technology, expanding its application to a broader offering of titanium components in the ELEOS™ Limb Salvage System. This marks another milestone in the company's continued investment in antibacterial innovation.
The new clearance extends NanoCept to additional titanium components of the ELEOS system, including proximal femurs, tibial baseplates and augments, and cemented bowed segmental stems. It also permits broader NanoCept coverage on previously cleared titanium components.
This advancement builds on the FDA clearance earlier this year for the application of NanoCept to titanium implants. It marks the fourth 510(k) clearance for NanoCept since the technology's groundbreaking De Novo authorization in April 2024 and reflects Onkos' ongoing commitment to expand the availability of its proprietary antibacterial technology.